Revenue
2019
2020
2021
2022
2023
2024
2025
Profound Medical Corp. (PROF)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2021
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $16.1M | $9.7M | $5.9M | $6.7M | $6.9M | $7.3M | $4.2M |
| Gross profit | $11.4M | $7.0M | $4.3M | $3.0M | $3.0M | $3.5M | $2.4M |
| Research & development | $20.6M | $17.0M | $14.4M | $14.7M | $15.3M | $9.9M | $9.4M |
| Operating expenses | $52.6M | $40.1M | $33.0M | $35.1M | $33.2M | $22.3M | $17.3M |
| Operating income | −$41.3M | −$33.1M | −$28.7M | −$32.1M | −$30.3M | −$18.9M | −$14.9M |
| EBITDAderived | −$40.7M | −$32.1M | −$27.5M | −$30.5M | −$28.4M | −$17.3M | −$13.4M |
| Net income | −$42.6M | −$27.8M | −$28.3M | −$28.7M | −$30.7M | −$21.6M | −$15.2M |
| Basic EPSper diluted share | $1.41 | $1.12 | $1.34 | $1.38 | $1.50 | $1.25 | $1.37 |
| Diluted EPSper diluted share | $1.41 | $1.12 | $1.34 | $1.38 | $1.50 | $1.25 | $1.37 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 16, 2025Form 4 | Menawat Arun SwarupCEO | BuyCommon Shares | 12.0K | $4.73 | $56.9K | 587.1K |
| May 15, 2025Form 4 | Menawat Arun SwarupCEO | BuyCommon Shares | 10.0K | $4.33 | $43.3K | 575.1K |